104 related articles for article (PubMed ID: 23167557)
1. Cutaneous tumor cell load correlates with survival in patients with Sézary syndrome.
Booken N; Nicolay JP; Weiss C; Klemke CD
J Dtsch Dermatol Ges; 2013 Jan; 11(1):67-79. PubMed ID: 23167557
[TBL] [Abstract][Full Text] [Related]
2. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.
Agar NS; Wedgeworth E; Crichton S; Mitchell TJ; Cox M; Ferreira S; Robson A; Calonje E; Stefanato CM; Wain EM; Wilkins B; Fields PA; Dean A; Webb K; Scarisbrick J; Morris S; Whittaker SJ
J Clin Oncol; 2010 Nov; 28(31):4730-9. PubMed ID: 20855822
[TBL] [Abstract][Full Text] [Related]
3. Sézary syndrome: a study of 176 patients at Mayo Clinic.
Kubica AW; Davis MD; Weaver AL; Killian JM; Pittelkow MR
J Am Acad Dermatol; 2012 Dec; 67(6):1189-99. PubMed ID: 22640839
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic tools in Sezary syndrome.
Möbs M; Knott M; Fritzen B; Pullmann S; Sterry W; Assaf C
G Ital Dermatol Venereol; 2010 Jun; 145(3):385-91. PubMed ID: 20461046
[TBL] [Abstract][Full Text] [Related]
5. Specific IgE toward allergenic molecules is a new prognostic marker in patients with Sézary syndrome.
Scala E; Abeni D; Palazzo P; Liso M; Pomponi D; Lombardo G; Picchio MC; Narducci MG; Russo G; Mari A
Int Arch Allergy Immunol; 2012; 157(2):159-67. PubMed ID: 21985996
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
[TBL] [Abstract][Full Text] [Related]
7. Sézary syndrome without erythroderma.
Henn A; Michel L; Fite C; Deschamps L; Ortonne N; Ingen-Housz-Oro S; Marinho E; Beylot-Barry M; Bagot M; Laroche L; Crickx B; Maubec E
J Am Acad Dermatol; 2015 Jun; 72(6):1003-9.e1. PubMed ID: 25981000
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and treatment of palmoplantar keratoderma and tinea pedis in patients with Sézary syndrome.
Martin SJ; Duvic M
Int J Dermatol; 2012 Oct; 51(10):1195-8. PubMed ID: 22994666
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in Sézary syndrome: a study of 28 patients.
Foulc P; N'Guyen JM; Dréno B
Br J Dermatol; 2003 Dec; 149(6):1152-8. PubMed ID: 14674891
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome.
Kim YH; Bishop K; Varghese A; Hoppe RT
Arch Dermatol; 1995 Sep; 131(9):1003-8. PubMed ID: 7661601
[TBL] [Abstract][Full Text] [Related]
11. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.
Vidulich KA; Talpur R; Bassett RL; Duvic M
Int J Dermatol; 2009 Mar; 48(3):243-52. PubMed ID: 19261011
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
[TBL] [Abstract][Full Text] [Related]
13. The diagnosis of Sézary syndrome on peripheral blood by flow cytometry requires the use of multiple markers.
Klemke CD; Brade J; Weckesser S; Sachse MM; Booken N; Neumaier M; Goerdt S; Nebe TC
Br J Dermatol; 2008 Sep; 159(4):871-80. PubMed ID: 18652582
[TBL] [Abstract][Full Text] [Related]
14. Sézary syndrome without erythroderma: A review of 16 cases at Mayo Clinic.
Thompson AK; Killian JM; Weaver AL; Pittelkow MR; Davis MD
J Am Acad Dermatol; 2017 Apr; 76(4):683-688. PubMed ID: 28012574
[TBL] [Abstract][Full Text] [Related]
15. High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of response.
Raphael BA; Shin DB; Suchin KR; Morrissey KA; Vittorio CC; Kim EJ; Gardner JM; Evans KG; Introcaso CE; Samimi SS; Gelfand JM; Rook AH
Arch Dermatol; 2011 Dec; 147(12):1410-5. PubMed ID: 21844430
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants in Patients With Sézary Syndrome.
Polansky M; Talpur R; Daulat S; Hosing C; Dabaja B; Duvic M
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):e83-93. PubMed ID: 25458083
[TBL] [Abstract][Full Text] [Related]
17. High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas.
Valencak J; Schmid K; Trautinger F; Wallnöfer W; Muellauer L; Soleiman A; Knobler R; Haitel A; Pehamberger H; Raderer M
J Dermatol Sci; 2011 Dec; 64(3):185-90. PubMed ID: 21937200
[TBL] [Abstract][Full Text] [Related]
18. Photopheresis does not improve survival in Sézary syndrome patients with bone marrow involvement.
de Misa RF; Harto A; Azaña JM; Belmar P; Díez E; Ledo A
J Am Acad Dermatol; 2005 Jul; 53(1):171-2. PubMed ID: 15965446
[No Abstract] [Full Text] [Related]
19. [Sezary syndrome treated by cytapheresis. Short and long-term results].
Benchikhi H; Zeitoun C; Bagot M; Wechsler J; Vaillant L; Joly P; Revuz J
Ann Dermatol Venereol; 1996; 123(4):247-50. PubMed ID: 8763747
[TBL] [Abstract][Full Text] [Related]
20. Sezary syndrome presenting with leonine facies and treated with low-dose subcutaneous alemtuzumab.
Oliveira A; Lobo I; Alves R; Lima M; Selores M
Dermatol Online J; 2011 Nov; 17(11):6. PubMed ID: 22136862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
